|
307 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...7879808182838485868788...9899» |
- Biomarker: Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=100, Recruiting, Sponsor: University of Nottingham
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV (clinicaltrials.gov) - Oct 3, 2012
P3, N=800, Active, not recruiting, Sponsor: Gilead Sciences
- ad6nsmut HCV vaccine / GSK, MVA-Nsmut HCV vaccine / GSK
New P1 trial, Combination therapy: HCV004: Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients (clinicaltrials.gov) - Oct 3, 2012
P1, N=9, Completed, Sponsor: Okairos
- ||||| ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Enrollment closed, Combination therapy: Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Oct 3, 2012
P3, N=700, Active, not recruiting, Sponsor: Celsion
Recruiting --> Active, not recruiting
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1/2 trial, Combination therapy: An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus (clinicaltrials.gov) - Oct 2, 2012
P1/2, N=120, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- Leukine (sargramostim) / Partner Therap
Trial withdrawal, Metastases, Viral vector: Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer (clinicaltrials.gov) - Oct 2, 2012
P1/2, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Completed --> Withdrawn
- |||| Caprelsa (vandetanib) / Sanofi
Trial completion, Combination therapy, Monotherapy, Metastases: VANGOGH: Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer (clinicaltrials.gov) - Oct 1, 2012
P2, N=174, Completed, Sponsor: AstraZeneca
Completed --> Withdrawn Active, not recruiting --> Completed
- |||||||||| Pegasys (pegylated interferon α -2a) / Roche
New P3 trial: A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253 (clinicaltrials.gov) - Sep 30, 2012
P3, N=88, Completed, Sponsor: Hoffmann-La Roche
- Enrollment change: UniRer: Hepatocellular Carcinoma Growth and Molecular Aggressiveness (clinicaltrials.gov) - Sep 28, 2012
P=N/A, N=78, Completed, Sponsor: Prof. Facchinetti Fabio
Active, not recruiting --> Completed N=100 --> 78
- Trial completion: UniRer: Hepatocellular Carcinoma Growth and Molecular Aggressiveness (clinicaltrials.gov) - Sep 28, 2012
P=N/A, N=78, Completed, Sponsor: Prof. Facchinetti Fabio
N=100 --> 78 Active, not recruiting --> Completed
- ||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion: PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-na (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=1611, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || entecavir / Generic mfg.
New P3 trial: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα (clinicaltrials.gov) - Sep 25, 2012
P3, N=128, Recruiting, Sponsor: Seoul National University Hospital
- Trial completion: CAESAR: Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir (clinicaltrials.gov) - Sep 25, 2012
P4, N=90, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents (clinicaltrials.gov) - Sep 25, 2012
P4, N=400, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ALS-2158 / J&J, Vertex
Trial termination: First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Sep 25, 2012
P1, N=78, Terminated, Sponsor: Alios Biopharma Inc.
Active, not recruiting --> Completed Recruiting --> Terminated; ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development.
- || Enrollment closed, MRI: PRIUS: Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=423, Active, not recruiting, Sponsor: Asan Medical Center
Recruiting --> Terminated; ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development. Recruiting --> Active, not recruiting
- | Trial completion: Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users (clinicaltrials.gov) - Sep 25, 2012
P2/3, N=1400, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy (clinicaltrials.gov) - Sep 23, 2012
P3, N=49, Completed, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial termination: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=119, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- Avastin (bevacizumab) / Roche
Enrollment change: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2012
P2, N=119, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=152 --> 119
- ||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Enrollment change, Combination therapy: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 (clinicaltrials.gov) - Sep 18, 2012
P2, N=168, Completed, Sponsor: Hoffmann-La Roche
N=152 --> 119 N=168168 --> 168
- ||| Pegasys (pegylated interferon ? -2a) / Roche, mericitabine (RG7128) / Gilead, Roche
Enrollment change, Combination therapy: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 (clinicaltrials.gov) - Sep 18, 2012
P2, N=413, Completed, Sponsor: Hoffmann-La Roche
N=168168 --> 168 N=413413 --> 413
- Enrollment change: Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol (clinicaltrials.gov) - Sep 18, 2012
P0, N=80, Completed, Sponsor: Chandan K Sen
N=413413 --> 413 N=140 --> 80
- | Pegasys (pegylated interferon ? -2a) / Roche
Trial completion: A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both (clinicaltrials.gov) - Sep 18, 2012
P1, N=30, Completed, Sponsor: Hoffmann-La Roche
N=140 --> 80 Active, not recruiting --> Completed
- |||| Vanihep (vaniprevir) / Merck (MSD)
Trial completion: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) (clinicaltrials.gov) - Sep 18, 2012
P2, N=285, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol (clinicaltrials.gov) - Sep 18, 2012
P0, N=80, Completed, Sponsor: Chandan K Sen
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Bioelectrical Impedance Vector Analysis in Cirrhotic Patients (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=310, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting --> Completed Active, not recruiting --> Completed
- deferasirox tablet for oral suspension / Generic mfg.
Trial completion: Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda (clinicaltrials.gov) - Sep 17, 2012
P3, N=10, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial termination: Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism (clinicaltrials.gov) - Sep 16, 2012
P4, N=240, Terminated, Sponsor: University of Vermont
Recruiting --> Completed Recruiting --> Terminated; Lack of funding
- Metastases: Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=60, Recruiting, Sponsor: Hospital Sirio-Libanes
- | ribavirin / Generic mfg.
New P4 trial: Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 (clinicaltrials.gov) - Sep 16, 2012
P4, N=190, Recruiting, Sponsor: King Abdulaziz Medical City
- New P2 trial: TRYPHON: Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver (clinicaltrials.gov) - Sep 16, 2012
P2, N=50, Recruiting, Sponsor: Jules Bordet Institute
- ribavirin / Generic mfg.
New P2 trial: Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant (clinicaltrials.gov) - Sep 16, 2012
P2, N=40, Active, not recruiting, Sponsor: Gilead Sciences
- | ribavirin / Generic mfg.
New P2 trial: Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation (clinicaltrials.gov) - Sep 16, 2012
P2, N=50, Active, not recruiting, Sponsor: Gilead Sciences
- Biomarker, Trial completion, MRI: Mrker: Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=134, Completed, Sponsor: University of Nottingham
Recruiting --> Terminated; Lack of funding Recruiting --> Completed
- Trial completion: Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=136, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Active, not recruiting --> Completed
- ||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion, IO biomarker, Compliance: MK-4031-267: Efficacy of Pegetron (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=2430, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- erlotinib / Generic mfg., celecoxib oral / Generic mfg.
Trial withdrawal: Celecoxib and Erlotinib in Treating Patients With Liver Cancer (clinicaltrials.gov) - Sep 12, 2012
P1/2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche
Trial initiation date: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - Sep 12, 2012
P2, N=0, Withdrawn, Sponsor: University of Regensburg
Active, not recruiting --> Withdrawn Initiation date: Mar 2012 --> Sep 2012
- erlotinib / Generic mfg., celecoxib oral / Generic mfg.
Enrollment change: Celecoxib and Erlotinib in Treating Patients With Liver Cancer (clinicaltrials.gov) - Sep 12, 2012
P1/2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Initiation date: Mar 2012 --> Sep 2012 N=50 --> 0
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment open: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 12, 2012
P2, N=30, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
N=50 --> 0 Not yet recruiting --> Recruiting
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
New P2 trial: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Sep 11, 2012
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
- | Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial: CONTRA: Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients (clinicaltrials.gov) - Sep 11, 2012
P4, N=80, Completed, Sponsor: Miguel Santin
- ||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion: PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-na (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=4598, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion, HEOR: PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt) (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=138, Completed, Sponsor: University Hospital, Tours
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ribavirin / Generic mfg.
Trial initiation date, Combination therapy: Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients (clinicaltrials.gov) - Sep 9, 2012
P1/2, N=3, Terminated, Sponsor: Medgenics Medical Israel Ltd.
Active, not recruiting --> Completed Initiation date: Nov 2011 --> Oct 2012
- Clinical: Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=58, Completed, Sponsor: University of Milan
- Clinical: Genetic Variant in Apolipoprotein C3 Gene and Fatty Liver in Obese Children (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=200, Recruiting, Sponsor: Far Eastern Memorial Hospital
- ||||||| Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
Trial completion: Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine (clinicaltrials.gov) - Sep 9, 2012
P3, N=2428, Completed, Sponsor: Dynavax Technologies Corporation
Initiation date: Nov 2011 --> Oct 2012 Active, not recruiting --> Completed
- | linifanib (ABT-869) / AbbVie
Trial termination, Metastases: Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 6, 2012
P3, N=1035, Terminated, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Terminated; See termination reason in detailed description